Skip to main content

Table 3 Analysing spinal progression in the cervical versus the lumbar spine after excluding baseline structural damage from the models to better depict the impact of sex

From: Site-specific assessment of spinal radiographic progression improves detection of TNF blocker-associated disease modification in axial spondyloarthritis: longitudinal observational data from the Swiss Clinical Quality Management Registry

  

Progression ≥ 1 mSASSS units per 2 years

Progression ≥ 1 new syndesmophyte per 2 years

Spinal segment

Variable

OR

95% CI

P value

OR

95% CI

P value

Cervical spine

TNFi use before radiographic interval yes/no

0.41

0.19; 0.87

0.02

0.37

0.13; 1.03

0.06

Male sex

2.68

1.09; 6.62

0.03

3.66

1.25; 10.7

0.02

Symptom duration (5 years)

1.47

1.25; 1.73

 < 0.001

1.49

1.23; 1.80

 < 0.001

Current smoking

1.05

0.53; 2.08

0.88

1.23

0.57; 2.66

0.60

HLA-B27

0.52

0.22; 1.22

0.13

0.39

0.15; 1.02

0.05

Number of exercise sessions per week

0.97

0.84; 1.13

0.72

0.84

0.71; 0.99

0.04

Peripheral arthritis

0.81

0.37; 1.76

0.59

0.59

0.22; 1.60

0.30

NSAID use at start of each radiographic interval

0.47

0.21; 1.04

0.06

0.40

0.14; 1.12

0.08

BMI 25–30 (reference: BMI < 25)

1.79

0.91; 3.52

0.09

1.35

0.62; 2.96

0.45

BMI > 30 (reference: BMI < 25)

0.92

0.29; 2.98

0.90

0.43

0.08; 2.24

0.32

Length of radiographic interval

0.52

0.23; 1.16

0.11

0.72

0.26; 1.96

0.52

Lumbar spine

TNFi use before radiographic interval yes/no

1.10

0.60; 2.03

0.76

0.73

0.35; 1.53

0.41

Male sex

5.63

2.36; 13.5

 < 0.001

5.52

1.85; 16.4

0.002

Symptom duration (5 years)

1.12

0.97; 1.30

0.13

1.11

0.94; 1.31

0.21

Current smoking

0.86

0.48; 1.55

0.61

0.69

0.33; 1.45

0.33

HLA-B27

0.56

0.27; 1.15

0.12

1.17

0.42; 3.27

0.77

Number of exercise sessions per week

0.98

0.87; 1.10

0.76

0.94

0.83; 1.08

0.39

Peripheral arthritis

1.18

0.65; 2.13

0.58

0.55

0.26; 1.17

0.12

NSAID use at start of each radiographic interval

1.39

0.68; 2.85

0.37

2.64

0.94; 7.42

0.07

BMI 25–30 (reference: BMI < 25)

1.01

0.54; 1.88

0.99

1.07

0.52; 2.22

0.85

BMI > 30 (Reference: BMI < 25)

1.44

0.65; 3.20

0.37

1.46

0.55; 3.88

0.44

Length of radiographic interval

1.30

0.58; 2.90

0.53

2.22

0.77; 6.38

0.14

  1. ASDAS Ankylosing Spondylitis Disease Activity Score, BMI Body mass index, HLA-B27 Human leucocyte antigen B27, mSASSS Modified Stoke Ankylosing Spondylitis Spinal Score, NSAID Nonsteroidal anti-inflammatory drug, TNFi Tumour necrosis factor inhibitor
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us